Leading US manufacturer of turnkey, mobile and modular cleanrooms and biocontainment facilities, Germfree Laboratories, has been acquired by EW Healthcare Partners
EW Healthcare Partners has acquired Germfree Laboratories, a leading US manufacturer of turnkey, mobile and modular cleanrooms and biocontainment facilities, as well as the equipment and services required for critical environments.
Founded in 1962, Germfree has continuously provided advanced solutions for healthcare and life science clients. The company has experienced significant growth over the years, with more than 200 facilities deployed on six continents and nearly 200 employees located in its 173,000 sqft (16,000 sqm), environmentally controlled, manufacturing plant in Ormond Beach, Florida.
Germfree's mobile and modular solutions are well-suited to service major, highly-regulated market segments in biopharma, compounding pharmacy, and biocontainment.
Together with EW, Germfree is positioned to maximise and scale our manufacturing to help fill the biomanufacturing capacity gap facing biopharma
"There is an increasing demand for mobile and modular cleanrooms in biopharma to keep pace with new technologies and platforms, capacity constraints and the demand for flexible solutions that are delivered quickly," said Evis Hursever, Managing Director at EW Healthcare Partners. "Germfree is addressing this demand for cleanrooms by designing and manufacturing advanced solutions for specialised and flexible cGMP-compliant manufacturing space. We look forward to working with Kevin and his team to further accelerate the company's growth into the fast-growing ATMP (advanced therapy medicinal products) sector."
"Together with EW, Germfree is positioned to maximise and scale our manufacturing to help fill the biomanufacturing capacity gap facing biopharma," said Kevin Kyle, Germfree's CEO. "EW is the perfect partner to foster and fuel Germfree's growth journey. Our shared mission to deliver innovation in healthcare and biopharma, and their commitment to our next stages of growth and long-term success, makes this a tremendous strategic fit."
Kyle added: "Further, EW's expertise and experience in advanced therapeutics and their extensive global network add synergy, as we expand our solutions to meet the fast-growing demands in segments such as cell and gene therapy."